This “Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market” report 2019-2024 provides an in-depth analysis of the current trends and future approximations to represent the forthcoming investment plans. The Europe Glucagon like Peptide – 1 (GLP – 1) Agonists market report presents the vendor landscape and consistent detailed analysis of the major vendors operating in the market. The report provides a competitive environment of the Europe Glucagon like Peptide – 1 (GLP – 1) Agonists market is based on company profiles and their efforts on increasing product value and production.
The Report Covers:
- Comprehensive research methodology of Europe Glucagon like Peptide – 1 (GLP – 1) Agonists market
- In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Europe Glucagon like Peptide – 1 (GLP – 1) Agonists market
- Insights about market determinants which are inspiring the Europe Glucagon like Peptide – 1 (GLP – 1) Agonists market
- Detailed and extensive market segments with regional distribution of forecasted revenues
- Extensive profiles and recent developments of market players Companies Mentioned
For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999723
Key Questions Answered in This Report:
- What are the market dynamics?
- What are the key market trends?
- What are the category growth drivers?
- What are the constraints on category growth?
- Who are the suppliers in this market?
- What are the demand-supply shifts?
- What are the major category requirements?
Key Market Trends: – Ever Increasing Burden of Diabetes in the European Region
As there is an exponential growth of the diabetes population, year on year, especially of type-2 diabetes, new innovative drugs are emerging in the market, for the ease of access to the patients.
With the increase in the diabetes population, the need and demand for diabetes drugs are expected to increase.
Other factors, such as better adoption than other therapies and government initiatives, are driving the diabetes drugs market.
Germany to Dominate the Europe GLP-1 Market
Among the studied countries, Germany is expected to lead the market, with a considerable 27.25% of the market share, followed by France.
Victoza holds the highest market share in the Europe region, and a similar trend is seen in Germany too. Victoza is a once-daily injection, used to control blood glucose levels by enhancing glucose-dependent insulin secretion by beta cells, suppressing inappropriate elevated glucagon secretion.
Trulicity is expected to have the highest growth during the forecast period (2019-2024) in the Europe region.
Purchase this Report (Price 4000 USD for single user license) – https://www.industryresearch.co/purchase/13999723
Detailed TOC of Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market 2019-2024:
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Exenatide
5.1.1.1 Byetta (Value and Volume 2012-2024)
5.1.1.2 Bydureon (Value and Volume 2012-2024)
5.1.2 Liraglutide
5.1.2.1 Victoza (Value and Volume 2012-2024)
5.1.3 Lixisenatide
5.1.3.1 Lyxumia (Value and Volume 2012-2024)
5.1.4 Dulaglutide
5.1.4.1 Trulicity (Value and Volume 2012-2024)
5.2 Geography
5.2.1 Europe
5.2.1.1 Germany (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.2 Spain (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.3 Italy (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly and AstraZeneca)
5.2.1.4 France (Value and Volume 2012-2024)
5.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide and Dulaglutide)
5.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.5 UK (Value and Volume 2012-2024)
5.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.6 Russia (Value and Volume 2012-2024)
5.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.7 Rest of Europe (Value and Volume 2012-2024)
5.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi
7.1.3 Eli Lilly
7.1.4 AstraZeneca
7.2 MARKET SHARE ANALYSIS
7.2.1 Novo Nordisk
7.2.2 Sanofi
7.2.3 Eli Lilly
7.2.4 AstraZeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
Contact Us:
Name: Ajay More
Phone: US +14242530807/ UK +44 20 3239 8187
Email: [email protected]
Our Other Reports:
Harvester Tyres Market 2019: Industry Demands, Top Key Players, Industry Analysis & Forecast By 2025
